SML4100

Vidofludimus

≥98% (HPLC)

• Synonym(e): IMU-838, 2-((3-Fluoro-3′-methoxy-[1,1′-biphenyl]-4-yl)carbamoyl)cyclopent-1-enecarboxylic acid, 2-[[(3-Fluoro-3′-methoxy[1,1′-biphenyl]-4-yl)amino]carbonyl]-1-cyclopentene-1-carboxylic acid, 2-[[2-Fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid, 4SC-101, IMU 838, IMU838, SC12267
• Empirische Formel (Hill-System): C₂₀H₁₈FNO₄
• CAS-Nummer: 717824-30-1
• Molekulargewicht: 355.36
• MDL number: MFCD18633262
• NACRES: NA.21
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to yellow
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: -10 to -25°C
• SMILES string: Fc1c(ccc(c1)c3cc(ccc3)OC)NC(=O)C2=C(CCC2)C(=O)O
• InChI: 1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)
• InChI key: XPRDUGXOWVXZLL-UHFFFAOYSA-N

Beschreibung

Biochem/physiol Actions

Orally active, potent dihydroorotate dehydrogenase (DHODH) inhibitor in cultures and in vivo.
Vidofludimus (4SC-101) is an orally active, potent dihydroorotate dehydrogenase (DHODH) inhibitor (human DHODH IC50 = 134 nM; IC50 = 13 µM against PHA-stimulated lymphocytes proliferation) that inhibits PHA-induced IL-17 secretion from human PBMCs (IC50 = 6 µM) and exhibits therapeutic efficacy in murine models of colitis (50-100 mg/kg/d via intragastric administration; chronic dextran sodium sulfate-induced and acute TNBS-induced colitis) and a rat model of renal transplantation in vivo (20 mg/kg/d p.o.).

Sicherheitshinweise

• Piktogramme: GHS07,GHS09
• Signalwort: Warning
• Gefahrencodes: H302,H400
• Sicherheitshinweise: P264 - P270 - P273 - P301 + P312 - P391 - P501
• Hazard Classifications: Acute Tox. 4 Oral - Aquatic Acute 1
• Lagerklasse: 11 - Combustible Solids
• Was ist los?: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable